Fulgent Genetics (FLGT) Enterprise Value (2015 - 2026)

Fulgent Genetics has disclosed Enterprise Value across 12 years of filings, most recently posting -$282.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$282.0 million, up 13.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$282.0 million (up 13.17% YoY), and the FY2025 annual result was -$341.4 million, down 30.2% from the prior year.
• Enterprise Value came in at -$282.0 million for Q1 2026 at Fulgent Genetics, up from -$341.4 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$216.6 million in Q3 2024 to a low of -$578.3 million in Q1 2022.
• The 5-year median for Enterprise Value is -$380.9 million (2025), against an average of -$386.0 million.
• Across the five-year window, Enterprise Value plunged 84.84% in 2022 and surged 53.38% in 2024, its largest moves.
• Fulgent Genetics' Enterprise Value stood at -$523.0 million in 2022, then gained by 18.37% to -$427.0 million in 2023, then jumped by 38.6% to -$262.2 million in 2024, then plunged by 30.2% to -$341.4 million in 2025, then grew by 17.4% to -$282.0 million in 2026.
• The last three Enterprise Value figures came in at -$282.0 million (Q1 2026), -$341.4 million (Q4 2025), and -$380.9 million (Q3 2025), per Business Quant data.